Anesthesia Management in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

NCT06398678 | Completed

• 1 other identifier: MAIEAHANEST
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

A combined approach of cytoreductive surgery (SRC) and hyperthermic intraperitoneal chemotherapy (HIPEC) represents a potential treatment option for patients diagnosed with primary or secondary gastrointestinal or gynaecological malignancies with peritoneal involvement. While the surgical phase of the operation macroscopically addresses the cancerous tissue, the HIPEC phase targets the microscopic tumour cells that remain after surgery (1). The surgical procedure known as SRC and HIPEC is one of the most complex surgical procedures, presenting numerous challenges for both the surgical and anaesthesia teams. The haemodynamic, haematological and metabolic changes that occur before, during and in the early postoperative period are associated with an increased risk of morbidity and mortality. It is therefore crucial for anaesthesia management to maintain normovolemia during surgery, compensate for hypothermia in the surgical phase and hyperthermia in the HIPEC phase, and maintain metabolic and haemodynamic balance throughout the entire procedure. The objective of this study was to retrospectively examine the anaesthesia management and clinical outcomes in patients who underwent cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in order to create literature information that can facilitate the early recognition and prevention of haemodynamic, haematological and metabolic problems that occur especially in the intraoperative and postoperative period.

Conditions

Cytoreductive Surgery; Hyperthermic Intraperitoneal Chemotherapy; Anesthesia

Outcome Measures

Primary Outcomes (6)

• Anesthesia Management in Hyperthermic Intraperitoneal Chemotherapy

  anaesthesia management in cytoreductive surgery and while hypertermic intraperitoneal chemotherapy

  01/01/2020 - 01/01/2024

• perioperative complications

  The potential complications associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be identified from the documented records.

  during the operation

• fluid transfusion amounts

  The quantity of fluid transfusion administered to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres.

  during the operation

• blood replacements

  The quantity and type of blood and blood products transfused to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from documented records in millilitres.

  during the operation

• procedure times

  The duration of the surgical procedure applied to the patient during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be determined from the documents recorded in minutes.

  during the operation

• 30-day mortality and morbidity

  The morbidity and mortality rate observed in the patient within 30 days of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be quantified as a percentage based on the documented records.

  post-operative 30 days

Study Arms (1)

Patients who had undergone cytoreductive surgery.

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study will include cases of patients over the age of 18 who underwent hyperthermic intraperitoneal chemotherapy with the closed method in accordance with the protocols determined by the Department of Surgical Oncology for 4 years retrospectively at the University of Health Sciences Şanlıurfa Mehmet Akif İnan Health Application and Research Center.

You may qualify if:

• patients with primary or secondary gastrointestinal or gynecologic malignancies with peritoneal involvement.
• Over 18 years of age

You may not qualify if:

• Over 80 years of age
• those with heart, lung and liver diseases

Sponsors & Collaborators

• Sanliurfa Mehmet Akif Inan Education and Research Hospital: lead

Study Sites (1)

University of Health Science Turkey Sanliurfa Mehmet Akif Inan Training and Research Hospital

Sanliurfa, 63050, Turkey (Türkiye)

Location

Related Publications (1)

• Kaya A, Karahan MA. Retrospective evaluation of anesthesia management and clinical outcomes in patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BMC Anesthesiol. 2025 Jul 30;25(1):369. doi: 10.1186/s12871-025-03241-5.

  PMID: 40739475 DERIVED

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: assistant professor

Study Record Dates

• First Submitted: May 1, 2024
• First Posted: May 3, 2024
• Study Start: January 1, 2020
• Primary Completion: January 1, 2024
• Study Completion: January 1, 2024
• Last Updated: May 6, 2024

Record last verified: 2024-05

Locations

TU (1)